LAB (Standard BioTools) Price-to-Operating-Cash-Flow: (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LAB Standard BioTools Inc LAB
33 GF Score
Price $0.65
GF Value $0.71
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Price-to-Operating-Cash-Flow?

As of today (2026-08-20), Standard BioTools's share price is $0.6463. Standard BioTools's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.21. Hence, Standard BioTools's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Standard BioTools's Price-to-Operating-Cash-Flow or its related term are showing as below:

LAB's Price-to-Operating-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 17.5
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Standard BioTools's Cash Flow from Operations per share for the three months ended in Jun. 2026 was $-0.03. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.21.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 44.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 6.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 11.60% per year.

During the past 13 years, Standard BioTools's highest 3-Year average Operating Cash Flow per Share Growth Rate was 62.50% per year. The lowest was -179.20% per year. And the median was 11.30% per year.

Standard BioTools Price-to-Operating-Cash-Flow Historical Data

* Premium members only.

The historical data trend for Standard BioTools's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools Price-to-Operating-Cash-Flow Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Standard BioTools Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LAB vs CV, ELMD, CATX: Price-to-Operating-Cash-Flow Comparison

For the Medical Devices subindustry, Standard BioTools's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Standard BioTools Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Price-to-Operating-Cash-Flow falls into.


LAB
33GF Score
Standard BioTools Inc LAB
Price-to-Operating-Cash-Flow is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools Price-to-Operating-Cash-Flow Calculation

Standard BioTools's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.6463/-0.207
=

Standard BioTools's Share Price of today is $0.6463.
Standard BioTools's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Is Standard BioTools (LAB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued. The current stock price of $0.65 is trading 9% below its estimated GF Value™ of $0.71. GuruFocus considers Standard BioTools to be Modestly Undervalued.

Key valuation signals for LAB:

  • Price-to-Operating-Cash-Flow:
  • GF Value™: $0.71 vs. price of $0.65 (9% below fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Standard BioTools Business Description

Other Exchanges FLB:Germany
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score

Get the complete analysis for LAB

Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.71
GF Value